NRNP 6665 Final Exam Test Questions, NR 603 Week 7
Edit Save
Students also studied
Mental Health Nursing Midterm Mental Health-FINAL EXAM Rasmus... HESI Mental Health Exam Review 20... Vsim pr
Teacher 97 terms Teacher 157 terms Teacher 500 terms Teacher
noblekid_Ke Preview Oblock872 Preview Klein_Juma Preview pat
Question 18: A. Dissociative disorders
Christine is a 9-year-old female who presents for care B. Post-traumatic stress disorder
after having been placed in the local foster care system. C. Impulse-control disorder
She has been in and out of foster care for the last 4 years D. Attachment disorder
after her parents were killed in an automobile accident.
Christine has been placed in a variety of homes and
residential care facilities. The PMHNP recognizes that
Christine is at high risk for:
Question 7: A. Caylee is at high risk for suicide and precautions should be taken
Caylee is a 5-year-old girl who is referred for evaluation B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
by child protective services. She was recently removed C. The history and reported symptoms are typical of depressive disorder in young
from her biological family and placed in foster care, as children
her home environment was reportedly unsafe due to D. This is a common situation when prepubertal children are removed from the
conditions of extreme neglect. Her foster mother reports biological parents regardless of how dysfunctional they are
that Caylee is very quiet and withdrawn and always
appears sad and disinterested in her surroundings;
however, she becomes very irritable when anything
unexpected or unplanned occurs. The foster mother
became very concerned when it appeared that Caylee
was hallucinating. The PMHNP considers that:
Question 2: A. There is a > 50% likelihood that Debi's younger sibling will develop depressive
Debi is a 15-year-old girl who is currently being treated symptoms
for depression. Her parents have been very proactive B. The mean length of major depressive episode in adolescents is 4 months
and involved in her care, and Debi has achieved C. 20 to 40% of adolescents who have major depressive disorder will develop
remission 2 months after beginning treatment with a bipolar I within 5 years
combination of pharmacotherapy and cognitive D. Adolescent-onset depression typically need long-term pharmacologic
behavioral therapy. While counseling Debi's parents management to prevent relapses
about important issues in management, the PMHNP
advises that:
,Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) Tricyclic antidepressant.
Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of
dopamine in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat depression and help
people quit smoking. It can also prevent depression caused by seasonal affective
disorder (SAD).
Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake
pump (transporter), -Desensitization of serotonin receptors, especially serotonin
1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine
reuptake pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages
10 and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant,
depression, Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
, Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-
HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Desiprimine (Norpramine) Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake
pump (serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage
increase or it may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
Desvenlafaxine (Pristiq) Dual serotonin and norepinephrine reuptake inhibitor-often classified as an
antidepressant.
-FDA approved to tx MDD.
-Off-label: Vasomotor sx's, fibromyalgia, GAD, Social Anx d/o, panic d/o, PTSD,
PMDD
-Dopamine is inactivated by norepinephrine reuptake in frontal cortex (which lack
dopamine transporters) med can increase dopamine neurotransmission in this part
of the brain
-
Risperidone (Risperdal) Atypical Antipsychotic (most "typical" of atypicals)
Side effects: EPS (dose-dependent), TD, significant increases in PRL (check PRL
levels)
--> most dopaminergic of Atypicals
IM formulation is available
Edit Save
Students also studied
Mental Health Nursing Midterm Mental Health-FINAL EXAM Rasmus... HESI Mental Health Exam Review 20... Vsim pr
Teacher 97 terms Teacher 157 terms Teacher 500 terms Teacher
noblekid_Ke Preview Oblock872 Preview Klein_Juma Preview pat
Question 18: A. Dissociative disorders
Christine is a 9-year-old female who presents for care B. Post-traumatic stress disorder
after having been placed in the local foster care system. C. Impulse-control disorder
She has been in and out of foster care for the last 4 years D. Attachment disorder
after her parents were killed in an automobile accident.
Christine has been placed in a variety of homes and
residential care facilities. The PMHNP recognizes that
Christine is at high risk for:
Question 7: A. Caylee is at high risk for suicide and precautions should be taken
Caylee is a 5-year-old girl who is referred for evaluation B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
by child protective services. She was recently removed C. The history and reported symptoms are typical of depressive disorder in young
from her biological family and placed in foster care, as children
her home environment was reportedly unsafe due to D. This is a common situation when prepubertal children are removed from the
conditions of extreme neglect. Her foster mother reports biological parents regardless of how dysfunctional they are
that Caylee is very quiet and withdrawn and always
appears sad and disinterested in her surroundings;
however, she becomes very irritable when anything
unexpected or unplanned occurs. The foster mother
became very concerned when it appeared that Caylee
was hallucinating. The PMHNP considers that:
Question 2: A. There is a > 50% likelihood that Debi's younger sibling will develop depressive
Debi is a 15-year-old girl who is currently being treated symptoms
for depression. Her parents have been very proactive B. The mean length of major depressive episode in adolescents is 4 months
and involved in her care, and Debi has achieved C. 20 to 40% of adolescents who have major depressive disorder will develop
remission 2 months after beginning treatment with a bipolar I within 5 years
combination of pharmacotherapy and cognitive D. Adolescent-onset depression typically need long-term pharmacologic
behavioral therapy. While counseling Debi's parents management to prevent relapses
about important issues in management, the PMHNP
advises that:
,Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) Tricyclic antidepressant.
Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of
dopamine in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat depression and help
people quit smoking. It can also prevent depression caused by seasonal affective
disorder (SAD).
Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake
pump (transporter), -Desensitization of serotonin receptors, especially serotonin
1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine
reuptake pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages
10 and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant,
depression, Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
, Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-
HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Desiprimine (Norpramine) Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake
pump (serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage
increase or it may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
Desvenlafaxine (Pristiq) Dual serotonin and norepinephrine reuptake inhibitor-often classified as an
antidepressant.
-FDA approved to tx MDD.
-Off-label: Vasomotor sx's, fibromyalgia, GAD, Social Anx d/o, panic d/o, PTSD,
PMDD
-Dopamine is inactivated by norepinephrine reuptake in frontal cortex (which lack
dopamine transporters) med can increase dopamine neurotransmission in this part
of the brain
-
Risperidone (Risperdal) Atypical Antipsychotic (most "typical" of atypicals)
Side effects: EPS (dose-dependent), TD, significant increases in PRL (check PRL
levels)
--> most dopaminergic of Atypicals
IM formulation is available
